Diclofenac Sodium Patent Expiration

1. Diclofenac Sodium patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5603929 FALCON PHARMS Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
Nov, 2014

(9 years ago)

US5653972 FALCON PHARMS Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
Nov, 2014

(9 years ago)




Market Authorisation Date: 04 May, 1998

Treatment: Treating or controlling ocular inflammation which comprises topically administering to affected eye a composition comprising an nsaid, a polymeric quaternary ammonium compound and boric acid

Dosage: SOLUTION/DROPS

More Information on Dosage

DICLOFENAC SODIUM family patents

Family Patents

2. Dyloject patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6407079 JAVELIN PHARMS INC Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
Jun, 2019

(5 years ago)

US8946292 JAVELIN PHARMS INC Formulations of low dose diclofenac and beta-cyclodextrin
Mar, 2027

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 23, 2017

Market Authorisation Date: 23 December, 2014

Treatment: Management of pain

Dosage: SOLUTION

How can I launch a generic of DYLOJECT before it's drug patent expiration?
More Information on Dosage

DYLOJECT family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Pennsaid patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539335 HORIZON Diclofenac topical formulation
Oct, 2027

(3 years from now)

US8563613 HORIZON Diclofenac topical formulation
Oct, 2027

(3 years from now)

US8871809 HORIZON Diclofenac topical formulation
Oct, 2027

(3 years from now)

US9101591 HORIZON Diclofenac topical formulation
Oct, 2027

(3 years from now)

US9168304 HORIZON Diclofenac topical formulation
Oct, 2027

(3 years from now)

US9132110 HORIZON Treatment of pain with topical diclofenac
Oct, 2027

(3 years from now)

US9168305 HORIZON Diclofenac topical formulation
Oct, 2027

(3 years from now)

US9066913 HORIZON Diclofenac topical formulation
Oct, 2027

(3 years from now)

US9220784 HORIZON Diclofenac topical formulation
Oct, 2027

(3 years from now)

US9339551 HORIZON Diclofenac topical formulation
Oct, 2027

(3 years from now)

US9339552 HORIZON Diclofenac topical formulation
Oct, 2027

(3 years from now)

US8252838 HORIZON Diclofenac topical formulation
Apr, 2028

(3 years from now)

US9370501 HORIZON Treatment of pain with topical diclofenac
Jul, 2029

(4 years from now)

US8618164 HORIZON Treatment of pain with topical diclofenac compounds
Jul, 2029

(4 years from now)

US8217078 HORIZON Treatment of pain with topical diclofenac
Jul, 2029

(4 years from now)

US9375412 HORIZON Treatment of pain with topical diclofenac
Jul, 2029

(4 years from now)

US9415029 HORIZON Treatment of pain with topical diclofenac
Jul, 2029

(4 years from now)

US8741956 HORIZON Treatment of pain with topical diclofenac
Jul, 2029

(4 years from now)

US8546450 HORIZON Treatment of pain with topical diclofenac compounds
Aug, 2030

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 16, 2017

Market Authorisation Date: 16 January, 2014

Treatment: Use of topical diclofenac sodium for treating pain; Use of topical diclofenac for treating pain; Use of topical diclofenac on a joint for treating osteoarthritis; Use of topical diclofenac on the knee...

Dosage: SOLUTION

How can I launch a generic of PENNSAID before it's drug patent expiration?
More Information on Dosage

PENNSAID family patents

Family Patents

4. Pennsaid patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8217078 NUVO PHARMS INC Treatment of pain with topical diclofenac
Jul, 2029

(4 years from now)

US8618164 NUVO PHARMS INC Treatment of pain with topical diclofenac compounds
Jul, 2029

(4 years from now)

US8741956 NUVO PHARMS INC Treatment of pain with topical diclofenac
Jul, 2029

(4 years from now)

US8546450 NUVO PHARMS INC Treatment of pain with topical diclofenac compounds
Aug, 2030

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Nov 04, 2012

Market Authorisation Date: 04 November, 2009

Treatment: Use of topical diclofenac on the knee and a second topical medication on the same knee; Use of topical diclofenac on the knee and a second topical prescription medication on the same knee; Combination...

Dosage: SOLUTION

How can I launch a generic of PENNSAID before it's drug patent expiration?
More Information on Dosage

PENNSAID family patents

Family Patents

5. Solaraze patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5929048 FOUGERA PHARMS Treatment of conditions and disease
Jun, 2014

(10 years ago)

US5639738 FOUGERA PHARMS Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
Jun, 2014

(10 years ago)

US5852002 FOUGERA PHARMS Treatment of conditions and disease
Jun, 2014

(10 years ago)

US5792753 FOUGERA PHARMS Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
Aug, 2015

(8 years ago)

US5914322 FOUGERA PHARMS Treatment of disease and conditions
Aug, 2015

(8 years ago)

US5985850 FOUGERA PHARMS Compositions comprising hyaluronic acid and drugs
Aug, 2015

(8 years ago)




Market Authorisation Date: 16 October, 2000

Treatment: Treatment of actinic keratoses

Dosage: GEL

How can I launch a generic of SOLARAZE before it's drug patent expiration?
More Information on Dosage

SOLARAZE family patents

Family Patents